Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Labetalol hydrochloride
Drug ID BADD_D01237
Description Labetalol is a racemic mixture of 2 diastereoisomers where dilevalol, the R,R' stereoisomer, makes up 25% of the mixture.[L7730] Labetalol is formulated as an injection or tablets to treat hypertension.[L7727,L7730] Labetalol was granted FDA approval on 1 August 1984.[L7724]
Indications and Usage Labetalol injections are indicated to control blood pressure in severe hypertension.[L7727] Labetalol tablets are indicated alone or in combination with antihypertensives like thiazides and loop diuretics to manage hypertension.[L7730]
Marketing Status approved
ATC Code C07AG01
DrugBank ID DB00598
KEGG ID D00600
MeSH ID D007741
PubChem ID 71412
TTD Drug ID D0A8XN
NDC Product Code 0591-0605; 0904-7109; 46016-0117; 29300-254; 36000-324; 0143-9320; 51407-614; 63629-2054; 63629-8902; 68382-798; 70518-2903; 71209-084; 71209-085; 71247-127; 71335-1410; 71335-2057; 71335-2063; 71335-2169; 0591-0607; 17337-0523; 58032-2025; 59349-0025; 17478-420; 23155-723; 47781-553; 63629-1164; 63629-1166; 63629-2212; 63629-2213; 63629-8900; 68083-111; 0409-2339; 70377-062; 70771-1163; 71209-083; 71247-130; 71335-2145; 24196-178; 82245-0203; 36000-320; 42806-329; 51407-615; 55154-4170; 68382-799; 70377-061; 63629-2215; 63629-2216; 70377-060; 70518-1546; 0615-8130; 72266-103; 72603-146; 72888-121; 53747-037; 0143-9366; 51407-616; 51662-1228; 55154-4747; 63629-1163; 68001-381; 70518-3411; 70518-3499; 70518-3557; 71247-126; 71930-035; 72611-738; 25021-317; 0143-9364; 0143-9622; 49884-122; 51655-322; 58657-603; 63629-1165; 65145-124; 68382-800; 71335-1242; 71930-037; 72611-734; 72888-120; 66039-962; 29300-252; 0143-9363; 49884-124; 50090-1290; 58657-602; 60687-439; 60760-628; 63629-2053; 63629-2214; 63629-8903; 65145-125; 68001-383; 71205-095; 71930-036; 0591-0606; 49452-3909; 51604-0017; 52423-0912; 23155-724; 0143-9623; 47781-554; 49884-123; 60760-784; 63629-1161; 63629-8901; 63629-9185; 0409-2267; 70518-1163; 70518-2728; 70771-1164; 70771-1165; 71335-9690; 0615-8131; 0904-7110; 50683-0590; 42806-328; 55154-2339; 60687-450; 63629-1162; 63629-2211; 63629-8898; 70518-1132; 72572-350; 72888-122; 0904-7111; 29300-253; 0143-9365; 42806-327; 50090-1161; 50090-1291; 55154-8192; 60687-461; 63629-2055; 63629-8899; 68001-382; 72266-102; 0641-6252; 12828-0070; 49452-3911; 66174-0003; 23155-725; 36000-322; 47781-586; 58657-604
UNII 1GEV3BAW9J
Synonyms Labetalol | Labetolol | Albetol | Apo-Labetalol | Apo Labetalol | ApoLabetalol | Trandate | Labetalol Hydrochloride | Hydrochloride, Labetalol | Normodyne | Presolol | SCH-19927 | SCH 19927 | SCH19927 | AH-5158 | AH 5158 | AH5158 | Dilevalol | Labetalol, (R,R)-Isomer | R,R-Labetalol | R,R Labetalol
Chemical Information
Molecular Formula C19H25ClN2O3
CAS Registry Number 32780-64-6
SMILES CC(CCC1=CC=CC=C1)NCC(C2=CC(=C(C=C2)O)C(=O)N)O.Cl
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Hypersensitivity10.01.03.003--
Hypotension24.06.03.002--
Jaundice cholestatic09.01.01.005--Not Available
Laryngospasm22.04.02.002--
Lichen planus23.03.08.001--Not Available
Mesenteric artery thrombosis07.15.02.008; 24.01.08.003--Not Available
Muscle spasms15.05.03.004--
Myopathy toxic15.05.05.006; 12.03.01.035--Not Available
Nasal congestion22.04.04.001--
Nausea07.01.07.001--
Oedema08.01.07.006; 14.05.06.010--Not Available
Orthostatic hypotension24.06.03.004; 17.05.01.020--Not Available
Pain08.01.08.004--
Paraesthesia23.03.03.094; 17.02.06.005--
Peyronie's disease21.12.01.002--Not Available
Pyrexia08.05.02.003--
Rash23.03.13.001--Not Available
Rash maculo-papular23.03.13.004--
Respiratory distress22.02.01.012--Not Available
Somnolence19.02.05.003; 17.02.04.006--
Syncope02.11.04.015; 24.06.02.012; 17.02.04.008--
Systemic lupus erythematosus15.06.02.003; 10.04.03.004; 23.03.02.006--Not Available
Thrombocytopenia01.08.01.002--Not Available
Urticaria23.04.02.001; 10.01.06.001--
Vertigo17.02.12.002; 04.04.01.003--
Visual impairment06.02.10.013--Not Available
Vomiting07.01.07.003--
Performance status decreased08.01.03.042--Not Available
Affect lability19.04.01.001--Not Available
Transaminases increased13.03.04.036--Not Available
The 2th Page    First    Pre   2 3    Next   Last    Total 3 Pages